In a postmenopausal woman receiving testosterone replacement therapy with elevated total and free testosterone levels, what management steps should be taken?

Management of Elevated Testosterone in Postmenopausal Women on Testosterone Replacement

Reduce the testosterone dose immediately to bring levels back into the physiologic premenopausal female range, as supraphysiologic testosterone concentrations from any preparation are explicitly not recommended and pose unnecessary risks. 1

Immediate Action Required

The 2019 Global Consensus Position Statement is unequivocal: testosterone preparations that result in supraphysiologic concentrations, including pellets and injections, are not recommended 1. Your patient's elevated total and free testosterone levels indicate overdosing, which must be corrected.

Step 1: Dose Reduction Algorithm

• Measure testosterone levels 3-6 weeks after any dose adjustment to confirm return to physiologic range 1
• Target testosterone concentrations should approximate premenopausal physiologic levels (not male reference ranges) 1
• If using transdermal preparations, reduce by the smallest increment available
• If using pellets or injections (which commonly cause supraphysiologic levels), discontinue and switch to transdermal formulations that allow better dose titration 1

Step 2: Clinical Assessment During Dose Adjustment

Evaluate for signs of androgen excess at each visit 1:

• Acne (new or worsening)
• Hirsutism (facial/body hair growth)
• Voice deepening
• Clitoromegaly
• Male-pattern hair loss

These adverse effects are dose-dependent and typically reversible with dose reduction 1.

Monitoring Protocol Going Forward

Once physiologic levels are achieved, the consensus guidelines mandate specific monitoring intervals 1:

• Every 6 months: Measure serum total testosterone to screen for overuse
• Every 6 months: Assess clinical response and signs of androgen excess
• At 6 months: If no benefit in sexual function (the only evidence-based indication), discontinue therapy entirely 1

Critical Pitfall to Avoid

Do not use male testosterone formulations at standard male doses. The FDA labeling for testosterone gel 1.62% specifies dose titration targets of 350-750 ng/dL for men 2—these are supraphysiologic for women. When off-label prescribing of male formulations is necessary due to lack of female-specific products, doses must be dramatically reduced to achieve female physiologic ranges 1.

Safety Considerations with Current Evidence

The evidence base has important limitations that make supraphysiologic dosing particularly concerning:

• Safety data exist only for physiologic doses up to 24 months 1
• Studies excluded women with cardiovascular or metabolic disease risk 1
• No long-term data exist for supraphysiologic dosing in women 1

While physiologic-dose testosterone shows no increased serious adverse events in short-term trials 1, elevated levels carry theoretical risks including:

• HDL cholesterol reduction (particularly with oral methyltestosterone) 3
• Potential cardiovascular effects (though data are insufficient) 1
• Unknown long-term breast cancer risk 1

Reassessing Treatment Indication

Since the only evidence-based indication for testosterone in postmenopausal women is hypoactive sexual desire disorder (HSDD) 1, confirm this diagnosis remains valid:

• Has sexual function improved on therapy?
• Was HSDD formally diagnosed after biopsychosocial assessment? 1
• Have other causes been addressed (relationship issues, medications, mood disorders)? 1

If the patient shows no benefit or the indication is unclear, discontinue testosterone therapy rather than continuing at any dose 1.

Formulation Considerations

If continuing therapy at reduced dose:

• Prefer transdermal patches or gels over oral or injectable formulations 4
• Avoid compounded "bioidentical" preparations unless no approved product is available, and only from pharmacies meeting Good Manufacturing Practice standards 1
• Never use pellets—they cannot be titrated and commonly cause supraphysiologic levels 1

The lack of FDA-approved female testosterone formulations in the U.S. creates challenges 1, 5, but this does not justify accepting supraphysiologic levels. Careful off-label use of male formulations at dramatically reduced doses, with meticulous monitoring, remains the pragmatic approach until female-specific products become available.